ADPT logo

Adaptive Biotechnologies Corporation (ADPT)

$28.49

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ADPT

Market cap

$4.61B

EPS

-0.44

P/E ratio

--

Price to sales

13.72

Dividend yield

--

Beta

2.182049

Price on ADPT

Previous close

$27.87

Today's open

$28

Day's range

$27.62 - $29.18

52 week range

$12 - $32.21

Profile about ADPT

CEO

Chad Robins

Employees

624

Headquarters

Seattle, WA

Exchange

Nasdaq Global Select

Shares outstanding

161876694

Issue type

Common Stock

ADPT industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ADPT

Adaptive Biotechnologies Highlights clonoSEQ's Central Role in Advancing MRD-Guided Care Across Hematology at ASH 2026

Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies Approximately 100 abstracts highlight the use of clonoSEQ to assess long-term treatment response, inform treatment strategies and guide patient management across lymphoid malignancies

news source

GlobeNewsWire • 15 hours ago

news preview

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), ), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. Jefferies Global Healthcare Conference in London, UKPresentation on Wednesday, November 18, 2026, at 4:00 p.m.

news source

GlobeNewsWire • Nov 10, 2026

news preview

Adaptive Biotechnologies Corporation (ADPT) Hits Fresh High: Is There Still Room to Run?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Adaptive Biotechnologies Q3 Earnings Call Highlights

Adaptive Biotechnologies NASDAQ: ADPT reported third-quarter net income and raised its full-year revenue outlook for its minimal residual disease business, as demand for its clonoSEQ cancer testing service increased in both clinical care and drug development.

news source

MarketBeat • Nov 5, 2026

news preview

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

Adaptive Biotechnologies Corporation (ADPT) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 5, 2026

news preview

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) --  Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026. “Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Adaptive Biotechnologies (ADPT) Q3 Earnings and Revenues Top Estimates

Adaptive Biotechnologies (ADPT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.15 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Adaptive Biotechnologies (ADPT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Adaptive Biotechnologies (ADPT) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Adaptive Biotechnologies: Getting Paid Every Step Of The Way To A Myeloma Cure

Adaptive Biotechnologies benefits from new NCCN guidelines and IMS cure definitions, positioning clonoSEQ as the standard for long-term myeloma MRD monitoring. MRD revenues grew 33% year-over-year to $66.2M, with clinical ASP up 7% and test volumes up 43%, driving adjusted EBITDA margin to 14%. Elimination of the OrbiMed revenue share and a $345M zero-coupon note refinancing provide ADPT with over five years of runway and remove a major growth tax.

news source

Seeking Alpha • Oct 27, 2026

news preview

Alger Small Cap Focus Fund Q3 2026 Portfolio Update

Forte Biosciences Inc., Twist Bioscience Corp., and Adaptive Biotechnologies Corp., were among the top contributors to performance. Cardinal Infrastructure Group, Inc., RBC Bearings Incorporated, and VSE Corporation were among the top detractors from performance. VSE Corporation shares detracted from performance during the quarter despite strong revenue growth, record profitability, and an improved full-year outlook.

news source

Seeking Alpha • Oct 23, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Adaptive Biotechnologies Corporation

Open an M1 investment account to buy and sell Adaptive Biotechnologies Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ADPT on M1